LT3766343T - Gyvūnai, išskyrus žmogų, turintys sukonstruotą imunoglobulino lambda lengvosios grandinės lokusą - Google Patents

Gyvūnai, išskyrus žmogų, turintys sukonstruotą imunoglobulino lambda lengvosios grandinės lokusą

Info

Publication number
LT3766343T
LT3766343T LTEP20180508.2T LT20180508T LT3766343T LT 3766343 T LT3766343 T LT 3766343T LT 20180508 T LT20180508 T LT 20180508T LT 3766343 T LT3766343 T LT 3766343T
Authority
LT
Lithuania
Prior art keywords
light chain
human animals
chain locus
lambda light
engineered immunoglobulin
Prior art date
Application number
LTEP20180508.2T
Other languages
English (en)
Lithuanian (lt)
Inventor
Chunguang GUO
Faith HARRIS
Vera VORONINA
John Mcwhirter
Natasha Levenkova
Lynn Macdonald
Naxin Tu
Andrew J Murphy
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of LT3766343T publication Critical patent/LT3766343T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEP20180508.2T 2016-11-04 2017-11-03 Gyvūnai, išskyrus žmogų, turintys sukonstruotą imunoglobulino lambda lengvosios grandinės lokusą LT3766343T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662417845P 2016-11-04 2016-11-04
US201762567932P 2017-10-04 2017-10-04

Publications (1)

Publication Number Publication Date
LT3766343T true LT3766343T (lt) 2022-06-10

Family

ID=62025924

Family Applications (3)

Application Number Title Priority Date Filing Date
LTEP20180508.2T LT3766343T (lt) 2016-11-04 2017-11-03 Gyvūnai, išskyrus žmogų, turintys sukonstruotą imunoglobulino lambda lengvosios grandinės lokusą
LTEP22164751.4T LT4082334T (lt) 2016-11-04 2017-11-03 Gyvūnai, išskyrus žmogų, turintys rekombinantinį imunoglobulino lambda lengvosios grandinės lokusą
LTEP17863293.1T LT3407709T (lt) 2016-11-04 2017-11-03 Gyvūnai, išskyrus žmogų, turintys sukonstruotą imunoglobulino lambda lengvosios grandinės lokusą

Family Applications After (2)

Application Number Title Priority Date Filing Date
LTEP22164751.4T LT4082334T (lt) 2016-11-04 2017-11-03 Gyvūnai, išskyrus žmogų, turintys rekombinantinį imunoglobulino lambda lengvosios grandinės lokusą
LTEP17863293.1T LT3407709T (lt) 2016-11-04 2017-11-03 Gyvūnai, išskyrus žmogų, turintys sukonstruotą imunoglobulino lambda lengvosios grandinės lokusą

Country Status (26)

Country Link
US (3) US10820582B2 (https=)
EP (4) EP4567119A3 (https=)
JP (5) JP6884860B2 (https=)
KR (4) KR20240055863A (https=)
CN (2) CN114369157A (https=)
AU (2) AU2017391167B2 (https=)
BR (1) BR112019008675A2 (https=)
CA (1) CA3038720A1 (https=)
CY (2) CY1123491T1 (https=)
DK (3) DK3766343T3 (https=)
ES (3) ES2915609T3 (https=)
FI (1) FI4082334T3 (https=)
HR (3) HRP20250695T1 (https=)
HU (3) HUE052087T2 (https=)
IL (2) IL266282B2 (https=)
LT (3) LT3766343T (https=)
MA (2) MA44091A (https=)
MX (2) MX385857B (https=)
PL (3) PL3407709T3 (https=)
PT (3) PT4082334T (https=)
RS (3) RS63390B1 (https=)
RU (2) RU2757665C2 (https=)
SG (2) SG10201913483XA (https=)
SI (3) SI4082334T1 (https=)
SM (3) SMT202200259T1 (https=)
WO (1) WO2018128691A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
CN103025884B (zh) 2010-07-26 2015-11-25 特里安尼公司 转基因动物和使用方法
EP3597038B1 (en) * 2012-02-01 2021-04-21 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
SG10201913483XA (en) 2016-11-04 2020-03-30 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain locus
EP3772927B1 (en) 2018-03-24 2025-01-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
IL314733A (en) 2018-03-26 2024-10-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
IL318469A (en) * 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
BR112021016173A2 (pt) 2019-02-22 2021-11-03 Regeneron Pharma Roedor geneticamente modificado, métodos de produção de um roedor geneticamente modificado e de produção de um anticorpo anti-nav1.7, célula ou tecido isolado de roedor, linhagem celular imortalizada, embrião de roedor, construto de ácido nucleico de direcionamento, e, hibridoma
DK3993623T3 (da) * 2019-07-01 2025-05-26 Zoetis Services Llc Transgene gnavere og fremgangsmåder til anvendelse deraf
JP2023529846A (ja) * 2020-06-02 2023-07-12 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド 共通軽鎖免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
US20220090060A1 (en) 2020-09-11 2022-03-24 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
CN116848254B (zh) 2020-12-16 2026-03-17 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
IL303865A (en) 2020-12-23 2023-08-01 Regeneron Pharma Methods for obtaining antibodies that bind transmembrane proteins and cells that produce them
KR20240110577A (ko) * 2021-11-10 2024-07-15 트리아니, 인코포레이티드 유전자이식 포유동물 및 이의 사용 방법
GB202217978D0 (en) * 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026035843A2 (en) 2024-08-06 2026-02-12 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012227A1 (en) * 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP2319301B1 (en) 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human Ig lambda light chain genes
ES2473596T3 (es) * 2003-07-15 2014-07-07 Therapeutic Human Polyclonals, Inc. Loci de inmunoglobulina humanizada
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
AU2009298458B2 (en) 2008-09-30 2015-10-08 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
JP5827127B2 (ja) * 2008-12-18 2015-12-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用
DK3622815T3 (da) 2009-07-08 2023-06-26 Kymab Ltd Gnavermodeller og terapeutiske molekyler
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
WO2011115476A1 (en) 2010-03-17 2011-09-22 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes later in life
PT3034608T (pt) 2010-06-22 2019-05-28 Regeneron Pharma Ratinhos expressando uma cadeia leve híbrida de imunoglobulina com uma região variável humana
ME02106B (me) 2011-02-25 2015-10-20 Regeneron Pharma Miševi sa adam6
SG11201401181YA (en) 2011-10-17 2014-04-28 Regeneron Pharma Restricted immunoglobulin heavy chain mice
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SG10201605675WA (en) * 2011-12-20 2016-09-29 Regeneron Pharma Humanized light chain mice
MX384291B (es) 2013-02-20 2025-03-14 Regeneron Pharma Modificación genética de ratas.
MY178882A (en) * 2013-02-20 2020-10-21 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
US9788534B2 (en) * 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
AU2014330922A1 (en) * 2013-10-01 2016-03-03 Kymab Limited Animal models and therapeutic molecules
KR102170502B1 (ko) 2013-12-11 2020-10-28 리제너론 파마슈티칼스 인코포레이티드 게놈의 표적화된 변형을 위한 방법 및 조성물
HRP20200529T1 (hr) 2014-06-06 2020-09-04 Regeneron Pharmaceuticals, Inc. Postupci i pripravci za modificiranje ciljnog lokusa
ES2781323T3 (es) 2014-06-23 2020-09-01 Regeneron Pharma Montaje de ADN mediado por nucleasas
KR102531016B1 (ko) 2014-11-21 2023-05-10 리제너론 파마슈티칼스 인코포레이티드 쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물
ES2947714T3 (es) 2014-12-19 2023-08-17 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida a través de múltiples direccionamientos en un solo paso
SG10201913483XA (en) 2016-11-04 2020-03-30 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain locus

Also Published As

Publication number Publication date
IL266282A (en) 2019-06-30
KR20210134059A (ko) 2021-11-08
SI4082334T1 (sl) 2025-06-30
AU2024200582B2 (en) 2026-04-09
SMT202000558T1 (it) 2020-11-10
PT4082334T (pt) 2025-05-21
EP3407709B9 (en) 2021-10-06
LT4082334T (lt) 2025-05-26
CA3038720A1 (en) 2018-07-12
DK3766343T3 (da) 2022-06-20
ES3035365T3 (en) 2025-09-02
MA53935A (fr) 2021-12-22
RU2021129958A (ru) 2021-11-02
AU2017391167B2 (en) 2024-02-15
US20260068860A1 (en) 2026-03-12
EP4567119A3 (en) 2025-09-24
KR102658529B1 (ko) 2024-04-19
KR102492433B1 (ko) 2023-01-30
CN114369157A (zh) 2022-04-19
IL266282B1 (en) 2023-12-01
ES2915609T3 (es) 2022-06-23
WO2018128691A8 (en) 2019-02-28
EP4567119A2 (en) 2025-06-11
PT3407709T (pt) 2020-08-20
JP2023053400A (ja) 2023-04-12
ES2823305T3 (es) 2021-05-06
PL3407709T3 (pl) 2021-01-11
EP3407709B1 (en) 2020-07-29
RU2019112589A3 (https=) 2021-03-30
IL308197A (en) 2024-01-01
MX2019005256A (es) 2019-08-05
RU2019112589A (ru) 2020-12-04
EP3407709A1 (en) 2018-12-05
MA44091A (fr) 2018-10-24
AU2024200582A1 (en) 2024-03-28
HUE071595T2 (hu) 2025-09-28
CY1123491T1 (el) 2022-03-24
NZ753456A (en) 2021-08-27
PT3766343T (pt) 2022-05-30
US20210029978A1 (en) 2021-02-04
KR20240055863A (ko) 2024-04-29
DK3407709T3 (da) 2020-08-31
KR20190076024A (ko) 2019-07-01
CN109996441B (zh) 2022-02-08
EP4082334B1 (en) 2025-03-26
FI4082334T3 (fi) 2025-06-10
KR102319069B1 (ko) 2021-11-01
RS60886B1 (sr) 2020-11-30
EP3766343B1 (en) 2022-05-11
US10820582B2 (en) 2020-11-03
WO2018128691A1 (en) 2018-07-12
SMT202200259T1 (it) 2022-07-21
JP2025166207A (ja) 2025-11-05
HUE052087T2 (hu) 2021-04-28
SI3407709T1 (sl) 2020-10-30
IL266282B2 (en) 2024-04-01
SI3766343T1 (sl) 2022-06-30
JP6884860B2 (ja) 2021-06-09
PL4082334T3 (pl) 2025-08-11
HUE061980T2 (hu) 2023-09-28
US20180125043A1 (en) 2018-05-10
EP3766343A1 (en) 2021-01-20
RS63390B1 (sr) 2022-08-31
SG10201913483XA (en) 2020-03-30
LT3407709T (lt) 2020-10-12
BR112019008675A2 (pt) 2019-07-09
DK4082334T3 (da) 2025-06-02
RU2757665C2 (ru) 2021-10-20
JP7386292B2 (ja) 2023-11-24
CY1125474T1 (el) 2025-05-09
JP2020501516A (ja) 2020-01-23
PL3766343T3 (pl) 2022-09-26
EP4082334A1 (en) 2022-11-02
SG11201903344XA (en) 2019-05-30
US12433264B2 (en) 2025-10-07
HRP20201403T1 (hr) 2020-11-27
JP2021090455A (ja) 2021-06-17
HRP20250695T1 (hr) 2025-08-01
MX385857B (es) 2025-03-18
JP2022130725A (ja) 2022-09-06
KR20230020550A (ko) 2023-02-10
SMT202500204T1 (it) 2025-07-22
MX2021010556A (es) 2021-10-01
CN109996441A (zh) 2019-07-09
AU2017391167A1 (en) 2019-05-30
RS66884B1 (sr) 2025-07-31
HRP20220888T1 (hr) 2022-10-28

Similar Documents

Publication Publication Date Title
IL266282A (en) Non-human animals with a transgenic immunoglobulin light chain locus
IL274797A (en) Non-human animals with engineered immunoglobulin light chain and uses thereof
IL285014A (en) Non–human animals having a hexanucleotide repeat expansion in a c9orf72 locus
HUE054612T2 (hu) Humanizált limfocitaaktiváló gén 3-t tartalmazó nem-humán állatok
PT3597037T (pt) Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito
DK3129400T3 (da) Ikke-humane dyr med humaniserede Fc-gamma-receptorer
IL253579A0 (en) Anti-light chain substituent antibodies
IL268049A (en) Human antibodies from transgenic rodents with multiple immunoglobulin heavy chain LOCIs
SG11201802698XA (en) Transgenic rabbit with common light chain